GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (LTS:0L35) » Definitions » Valuation Rank

Sarepta Therapeutics (LTS:0L35) Valuation Rank


View and export this data going back to 2018. Start your Free Trial

What is Sarepta Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Sarepta Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Sarepta Therapeutics (LTS:0L35) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (LTS:0L35) » Definitions » Valuation Rank
Comparable Companies
RPRX INCY UTHR TECH BMRN ROIV LEGN VKTX CERE ASND OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
SRPT:USA AB3A:Germany S1RP34:Brazil
Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Website
https://www.sarepta.com
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.